SERO Serologicals (MM)

Serologicals Corporation (NASDAQ: SERO) today announced that Rashu Bhargava Seth, from the University of Texas Southwestern Medical Center at Dallas, has been named the 2006 Young Cell Signaller. She was chosen from among five finalists and more than 86 entries in its Upstate 2006 Young Cell Signaller Award competition at the Third Annual Cell Signalling Symposium. Seth's presentation was entitled "Understanding Host Antiviral Signaling Pathways." Entries were submitted as abstracts by Ph.D. students and first time post-doctorates competing to win $17,000 worth of support funding for their laboratory, a personal cash prize of $8,500 and a trophy. The finalists presented their work during the recent Cell Signalling Symposium held in Dundee, Scotland (U.K.), and were judged by symposium attendees and an experienced scientific panel including two of the world's most cited scientists, Sir Philip Cohen and Professor Dario Alessi. Each entrant gave a 25-30 minute presentation, followed by a five-minute question and answer period. "The 3rd Annual Cell Signalling Symposium attracted some of the best researchers in the field of innate and adaptive immune system. The calibre of research presentations and discussions at the symposium was outstanding," said Seth. "The Upstate Young Cell Signaller competition provides an excellent platform for students and post-docs to present their work. The ideas and suggestions I got for my work will really help me with my project. It is an honour and big encouragement for me to receive this award. The cash award for my laboratory will be used to buy reagents for my project." The four other finalists and their presentations were: Marzena Bienko, from the John Wolfgang Goethe University, Frankfurt, presenting "Novel Ubiquitin-Binding Domains in Y-Family Polymerases Regulate Translesion Synthesis." Kate Jeffrey, from the Garvan Institute of Medical Research, presenting "PAC-1 Phosphatase: as key positive regulator of immune cell function and inflammatory responses." Nina Jones, from the Samuel Lunenfeld Research Institute, presenting "Nck Adaptors Link Nephrin to the Actin Cytoskeleton of Kidney Podocytes." Omar Perez, from the Stanford University School of Medicine, presenting "Activation State Analysis in Single Cells: a systems biology approach to understanding intracellular mechanisms." Serologicals Corporation President and CEO David Dodd commented on the finalists, "These young people represent the future of our industry in medical research. I congratulate all of them and wish them the best in their future work." The Third Annual Cell Signalling Symposium was held June 11-14, 2006, at the Apex City Quay Hotel, Dundee, U.K. It was co-sponsored by Upstate and the MRC Protein Phosphorylation Unit at the University of Dundee. The focus for the three day, not-for-profit meeting was 'Signalling in the Innate and Adaptive Immune Systems'. Upstate is a leading research discovery provider of the highest quality cell signaling products and services to the life science market. Its customers are biomedical researchers at drug discovery companies and academic institutions in the key disciplines of oncology, immunology, proteomics, cardiology and neurology. Known for its enabling, innovative solutions to help understand the biology of kinases, chromatin, g-proteins and cytokines, Upstate's advanced cell biology tools - drug screening services, enzymes, state specific antibodies, siRNA kits and multiplex assays - are used by thousands of customers worldwide, everyday, to accelerate human health. Upstate, a Serologicals company, is headquartered in Temecula, California, and offices in Dundee, Scotland. For more information, please visit our website www.upstate.com. Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, Georgia, is a global provider of biological products and enabling technologies, which are essential for the research, development and manufacturing of biologically based life science products. The Company's products and technologies are used in a wide variety of innovative applications within the areas of oncology, hematology, immunology, cardiology and infectious diseases, as well as in the study of molecular biology. Serologicals has approximately 1,000 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO. On April 25, 2006, Serologicals entered into an Agreement and Plan of Merger with Millipore Corporation and one of its wholly-owned subsidiaries, pursuant to which Millipore Corporation will acquire Serologicals. For more information, please visit our website: www.serologicals.com. Serologicals is a registered trademark of Serologicals Royalty Company.